AU776214B2 - Tyrosine derivatives with anti-leukotriene activity - Google Patents

Tyrosine derivatives with anti-leukotriene activity Download PDF

Info

Publication number
AU776214B2
AU776214B2 AU33742/01A AU3374201A AU776214B2 AU 776214 B2 AU776214 B2 AU 776214B2 AU 33742/01 A AU33742/01 A AU 33742/01A AU 3374201 A AU3374201 A AU 3374201A AU 776214 B2 AU776214 B2 AU 776214B2
Authority
AU
Australia
Prior art keywords
group
formula
compounds
pharmaceutical preparation
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU33742/01A
Other languages
English (en)
Other versions
AU3374201A (en
Inventor
Francesco Makovec
Walter Peris
Lucio Claudio Rovati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rottapharm SpA
Original Assignee
Rotta Research Laboratorium SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rotta Research Laboratorium SpA filed Critical Rotta Research Laboratorium SpA
Publication of AU3374201A publication Critical patent/AU3374201A/en
Application granted granted Critical
Publication of AU776214B2 publication Critical patent/AU776214B2/en
Assigned to ROTTAPHARM S.P.A. reassignment ROTTAPHARM S.P.A. Request to Amend Deed and Register Assignors: ROTTA RESEARCH LABORATORIUM S.P.A.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU33742/01A 2000-02-09 2001-02-07 Tyrosine derivatives with anti-leukotriene activity Ceased AU776214B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITTO2000A000127 2000-02-09
IT2000TO000127A IT1320162B1 (it) 2000-02-09 2000-02-09 Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
PCT/EP2001/001315 WO2001058892A1 (en) 2000-02-09 2001-02-07 Tyrosine derivatives with anti-leukotriene activity

Publications (2)

Publication Number Publication Date
AU3374201A AU3374201A (en) 2001-08-20
AU776214B2 true AU776214B2 (en) 2004-09-02

Family

ID=11457397

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33742/01A Ceased AU776214B2 (en) 2000-02-09 2001-02-07 Tyrosine derivatives with anti-leukotriene activity

Country Status (11)

Country Link
US (1) US6605722B2 (enExample)
EP (1) EP1255749B1 (enExample)
JP (1) JP4817577B2 (enExample)
AT (1) ATE354571T1 (enExample)
AU (1) AU776214B2 (enExample)
CA (1) CA2399451C (enExample)
DE (1) DE60126745T2 (enExample)
ES (1) ES2282234T3 (enExample)
IT (1) IT1320162B1 (enExample)
PT (1) PT1255749E (enExample)
WO (1) WO2001058892A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001261654A (ja) * 2000-03-21 2001-09-26 Mitsui Chemicals Inc キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬
US7074810B2 (en) * 2002-10-07 2006-07-11 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
CN103145616B (zh) 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
CN102351791B (zh) 2006-01-27 2014-10-29 菲布罗根有限公司 使低氧诱导因子(hif)稳定的氰基异喹啉化合物
AU2007234408B2 (en) 2006-04-04 2011-05-19 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
US7687705B2 (en) * 2006-04-10 2010-03-30 Alabama A&M University Institute Efficient thermoelectric device
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
WO2013134660A1 (en) 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
SG11201500234YA (en) 2012-07-16 2015-02-27 Fibrogen Inc Process for making isoquinoline compounds
EP3470397B1 (en) 2012-07-16 2021-12-29 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
SG10202009266PA (en) 2013-01-24 2020-10-29 Fibrogen Inc Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004246A1 (en) * 1994-08-01 1996-02-15 Laboratorios Menarini S.A. Phenylacetamides having leukotriene-antagonistic action
DE19823722A1 (de) * 1998-05-27 1999-12-02 Merckle Gmbh Chinolinylmethoxyaryl-Verbindungen als duale Inhibitoren der Cyclooxygenase und 5-Lipoxygenase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1261835A (en) 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
FI94342C (fi) 1988-03-29 1995-08-25 Ciba Geigy Ag Menetelmä uusien alkanofenonien valmistamiseksi
HU222344B1 (hu) 1990-10-12 2003-06-28 Merck Frosst Canada & Co. Eljárás telítetlen hidroxi-alkil-kinolinsavak, és ezeket tartalmazó gyógyszerkészítmények előállítására
US5508408A (en) 1993-09-10 1996-04-16 Ciba-Geigy Corporation Quinoline compound
JPH11506425A (ja) 1995-04-21 1999-06-08 第一製薬株式会社 エチニルチアゾール誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004246A1 (en) * 1994-08-01 1996-02-15 Laboratorios Menarini S.A. Phenylacetamides having leukotriene-antagonistic action
DE19823722A1 (de) * 1998-05-27 1999-12-02 Merckle Gmbh Chinolinylmethoxyaryl-Verbindungen als duale Inhibitoren der Cyclooxygenase und 5-Lipoxygenase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. MED. CHEM., VOL. 39, NO. 14, 5 JULY 1996, PP. 2629-2654 *

Also Published As

Publication number Publication date
ITTO20000127A1 (it) 2001-08-09
CA2399451C (en) 2009-09-22
ES2282234T3 (es) 2007-10-16
EP1255749A1 (en) 2002-11-13
US20030087910A1 (en) 2003-05-08
DE60126745D1 (de) 2007-04-05
JP4817577B2 (ja) 2011-11-16
DE60126745T2 (de) 2007-10-31
PT1255749E (pt) 2007-05-31
US6605722B2 (en) 2003-08-12
EP1255749B1 (en) 2007-02-21
AU3374201A (en) 2001-08-20
CA2399451A1 (en) 2001-08-16
WO2001058892A1 (en) 2001-08-16
JP2003522768A (ja) 2003-07-29
IT1320162B1 (it) 2003-11-18
ATE354571T1 (de) 2007-03-15

Similar Documents

Publication Publication Date Title
CA1333802C (en) Substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic acid derivatives
DE10253426B4 (de) Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
US8993554B2 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
KR900005657B1 (ko) 1H-이미다조[4,5-c]퀴놀린 화합물및 그것의 제조방법
US6251923B1 (en) Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and process for their preparation
JP5524343B2 (ja) ベンゾジアゼピンブロモドメイン阻害剤
EP1255749B1 (en) Tyrosine derivatives with anti-leukotriene activity
JP2002530377A (ja) Ｎｋ−３およびｎｋ−２受容体アンタゴニストとしてのキノリン−４−カルボキシアミド誘導体
KR20200101470A (ko) 소마토스타틴 조절제의 제조 방법
US4994468A (en) Imidazoquinolone derivatives
EP0053789B1 (en) 2-pyridinecarboxamide derivative, process for preparing same and pharmaceutical composition, useful as an anti-allergic agent
CA2160859A1 (en) Quinoxalines, a process for their preparation, and their use
CN116082310A (zh) 联吡啶酰胺类衍生物及其制备和应用
US6121286A (en) Tetrazole derivatives
TW202035406A (zh) 作為cdk-hdac雙通路抑制劑的雜環化合物
CN111344284B (zh) 用作异戊二烯半胱氨酸羧甲基转移酶抑制剂的化合物
US5821245A (en) Use of naphthalene derivatives in treating lung carcinoma
IE46505B1 (en) Pyrido (2,1-b) quinazoline derivatives
EP2326645B1 (en) Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it
WO2006035452A1 (en) Novel pseudomorph of valaciclovir hydrochloride
AU707032B2 (en) Novel 1-ethyl-1,2-dihydro-2-oxo-3-methylamino-quinoxaline derivatives, their use as medicinal products and the pharmaceutical compositions comprising them
US5484924A (en) Imidazonaphthyridine derivatives
WO1996002506A1 (en) Quinoline derivatives as leukotriene antagonists
HK1153195B (en) Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase